Paper Details

  1. Home
  2. Paper Details

Benralizumab for eosinophilic gastritis: a single-site, randomised, double-blind, placebo-controlled, phase 2 trial.

Author: AboniaJuan P, BoltonScott M, CollinsMargaret H, DevonshireAshley L, DiTommasoLauren A, KellnerErinn S, KliewerKara L, KlionAmy D, KunnathurVidhya A, LylesJohn L, MartinLisa J, MukkadaVincent A, Murray-PetzoldCristin, PutnamPhilip E, RosenbergChen E, RothenbergMarc E, SchwartzJustin T, ShodaTetsuo, ZhangXue

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., IntramuralFunding provided by the NIH for research projects within the NIH.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Eosinophilic gastritis is a condition where eosinophils accumulate in the stomach, but their role in the disease and the effect of their depletion are unclear. Benralizumab, an eosinophil-depleting antibody, may improve outcomes in eosinophilic gastritis. This study aims to evaluate the efficacy and safety of benralizumab in patients with this condition.
Paper Details　
Original Abstract of the Article :
In eosinophilic gastrointestinal diseases, the role of eosinophils in disease pathogenesis and the effect of eosinophil depletion on patient outcomes are unclear. Benralizumab, an eosinophil-depleting monoclonal antibody that targets the interleukin-5 receptor α, might eliminate gastric tissue eosin...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/37336228

データ提供：米国国立医学図書館（NLM）

Targeting Eosinophils in Eosinophilic Gastritis: A New Frontier in Treatment

Eosinophilic gastrointestinal diseases (EGIDs) are a group of inflammatory conditions characterized by the accumulation of eosinophils in the gastrointestinal tract. While the exact role of eosinophils in disease pathogenesis remains under investigation, their involvement suggests a potential therapeutic target. This research focuses on benralizumab, a monoclonal antibody that depletes eosinophils by targeting the interleukin-5 receptor α. The study aims to evaluate the efficacy and safety of benralizumab in patients with eosinophilic gastritis, a specific type of EGID affecting the stomach.

Benralizumab: A Potential Weapon in the Fight Against Eosinophilic Gastritis

The research found that benralizumab was well-tolerated and had a favorable safety profile. While the study was limited by its small sample size, it suggests that benralizumab may be a promising treatment option for eosinophilic gastritis. This research offers hope for individuals with eosinophilic gastritis, who often face challenges finding effective treatment options.

A New Avenue for Eosinophilic Gastritis Treatment: More Research Needed

While this study provides promising preliminary results, further research is needed to confirm the efficacy and long-term safety of benralizumab in a larger population. This research highlights the importance of targeted therapies in the management of EGIDs. Just as a desert traveler chooses the right tools for their journey, understanding the specific mechanisms of the disease can lead to more effective treatment strategies.

Dr.Camel's Conclusion

This research showcases the potential of benralizumab as a novel treatment for eosinophilic gastritis. However, further investigation is crucial to validate its efficacy and safety in a larger cohort of patients. The study highlights the need for targeted therapies that address the specific mechanisms of EGIDs, offering hope for improved treatment outcomes for patients with these conditions.

Date :
  1. Date Completed 2023-08-14
  2. Date Revised 2023-12-08
Further Info :

Pubmed ID

37336228

DOI: Digital Object Identifier

NIHMS1911974

Related Literature

Article Analysis
・Effective treatment of eosinophilic disorders
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.